Welcome to our dedicated page for Neuraxis SEC filings (Ticker: NRXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeurAxis, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a medical technology company built around PENFS neuromodulation. Its 8-K reports cover preliminary operating results, FDA 510(k) clearance for PENFS indications, at-the-market common stock offering arrangements under a Form S-3 registration statement, related prospectus supplements and legal opinions, and material agreements involving licensed neuromodulation assets.
NeurAxis proxy materials disclose annual meeting matters, director elections, auditor ratification, equity incentive plan amendments, an employee stock purchase plan, and voting rights involving common stock and Series B Preferred Stock. The filing record also documents corporate governance, stock-based compensation plans, material contract changes, and risk-bearing financing mechanisms tied to its commercialization strategy.
Carrico Brian Allen reported acquisition or exercise transactions in this Form 4 filing.
Neuraxis, Inc. (NRXS) reported that Chief Executive Officer and director Brian Allen Carrico received a grant of 193,329 restricted stock units (RSUs) as equity compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period. Following this award, his directly held RSU-based common stock position reported in this filing is 193,329 shares.
Neuraxis, INC director Aharon Gil reported three acquisitions of Common Stock of NRXS. On 2026-08-13, he received 43,930 shares at $6.28 per share as compensation for serving as an independent director. On 2026-07-29, he and Rosalind Master Fund L.P. received 2,226 and 40,068 shares, respectively, as stock dividends on their Series B Preferred Stock, based on accrued 8.5% cumulative dividends divided by $2.38. The 40,068-share position is reported as indirect ownership through Rosalind Advisors, Inc., with beneficial ownership disclaimed except for each party’s pecuniary interest, and total indirect holdings after these transactions are 548,123 shares.
NeurAxis, Inc. reported rapid top-line growth but continued losses for the quarter and six months ended June 30, 2026. Net sales rose to $1.93 million for the quarter and $3.54 million year-to-date, driven by broader insurance coverage following IB-Stim’s Category I CPT code and higher average selling prices. Gross margin remained high at 85.9–86.1%, yielding gross profit of $3.05 million for the six months.
Operating loss was $3.87 million and net loss $3.85 million year-to-date, slightly better than 2025 but still significant. Cash and cash equivalents increased to $8.32 million, largely from equity offerings and warrant exercises, supporting working capital of $6.32 million. Stockholders’ equity improved to $6.74 million as of June 30, 2026.
The company emphasizes going-concern risks, citing a history of operating losses and dependence on continued sales growth and external financing. It highlights a focused neuromodulation portfolio (IB-Stim and RED), expanding clinical studies, and ongoing efforts to secure broader payor coverage as key drivers of future performance.
Neuraxis, Inc. is registering for resale up to 1,923,194 shares of common stock held by existing security holders. This is a secondary offering: only the selling stockholders will receive proceeds from any sale, while Neuraxis will not receive any cash from these transactions.
The registered shares consist of 849,212 issued shares, 923,776 shares underlying RSUs, and 150,206 shares issued to directors. As of July 22, 2026, 12,477,309 shares of common stock were outstanding. The selling stockholders may sell shares over time through various methods, including market and negotiated transactions, and may be deemed underwriters depending on how they sell.
Neuraxis is a growth-stage medical technology company focused on neuromodulation therapies for gastrointestinal disorders, led by its proprietary IB-Stim PENFS device for pediatric and adult functional abdominal pain and its RED device for rectal neuromuscular evaluation. The company is listed on the NYSE American under the symbol NRXS, with a closing share price of $6.59 on August 3, 2026, and qualifies as an emerging growth company, with extensive risk factors incorporated by reference.
Neuraxis, Inc. (NRXS) is reported to have a significant shareholder group led by Bigger Capital Fund, LP and related entities. As of August 3, 2026, Bigger Capital beneficially owned 731,377 shares of common stock, while District 2 Capital Fund LP beneficially owned 94,352 shares. Based on 12,477,309 shares outstanding as of July 22, 2026, Bigger Capital and its general partner Bigger Capital Fund GP, LLC may be deemed to beneficially own about 5.86% of the common stock, and Michael Bigger, through various entities and personal holdings, may be deemed to beneficially own about 6.67%. The report also notes additional shares issuable upon exercise of warrants subject to a 4.99% beneficial ownership limitation, which are excluded from these percentage calculations.
Neuraxis, Inc. filed Amendment No. 1 to its Form S-3 registration statement (File No. 333-297651) as an exhibit-only filing. The amendment updates Item 16 to add Exhibit 23.1, the consent of Rosenberg Rich Baker Berman, P.A., while leaving the prospectus and the remainder of Part II unchanged.
The document also restates the exhibits list, confirms previously filed legal opinions and powers of attorney, and includes signatures from Chief Executive Officer Brian Carrico and Chief Financial Officer Timothy Henrichs dated July 30, 2026.
Neuraxis, Inc. is registering up to 1,923,194 shares of common stock for resale by existing selling stockholders under a shelf registration. These shares, called the Selling Stockholder Shares, may be sold from time to time at market, negotiated or fixed prices through various methods, including brokered transactions, hedging and short sales, as described in the plan of distribution.
The company will not receive any proceeds from the sale of these shares; all proceeds will go to the selling stockholders, while Neuraxis covers registration-related expenses. As of July 22, 2026, there were 12,477,309 shares of common stock outstanding and the NYSE American closing price was $6.87 per share. The registered shares consist of 849,212 issued shares, 923,776 shares underlying RSUs, and 150,206 shares issued to directors for board service.
Neuraxis is a growth-stage medical technology company focused on neuromodulation therapies for gastrointestinal disorders using its proprietary IB-Stim PENFS device for pediatric and adult functional abdominal pain and its RED rectal expulsion device. The company qualifies as an emerging growth company and directs investors to detailed risk factors in its 2025 Form 10-K and other incorporated SEC filings.
Neuraxis, Inc. reported that its Board of Directors authorized and the company declared a stock dividend on its Series B Preferred Stock for the second quarter of 2026. This dividend will be paid in shares of Neuraxis common stock.
The number of common shares each Series B holder receives will equal that holder’s accrued and unpaid dividends from April 1, 2026 through the record date, divided by $2.38. A total of approximately 80,463 shares of common stock are expected to be issued. The dividend is payable on July 29, 2026 to Series B holders of record as of the close of business on July 21, 2026. No fractional shares will be issued; instead, any fractional entitlement will be settled in cash using the same $2.38 figure.
Neuraxis, Inc. held its annual stockholder meeting, with 10,206,763 votes represented, equivalent to approximately 73.51% of outstanding voting power, establishing a quorum. Six directors were elected, each receiving at least 96.64% of votes cast for their seats.
Stockholders ratified the appointment of Rosenberg Rich Baker Berman, P.A. as independent auditor for the year ending December 31, 2026, with 10,187,191 votes in favor. They also approved an amendment to the 2022 Omnibus Securities and Incentive Plan, which again revised Section 5.1, and approved the Neuraxis, Inc. 2025 Employee Stock Purchase Plan.
Before the meeting, the board amended Section 5(c) of the Employee Stock Purchase Plan so that no employee may receive purchase rights if, immediately after grant, the employee would own 10% or more of the company’s voting power or value, replacing the original 5% limitation.